Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Name: Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Published: 2021
License: Public Domain

Merck Sharp & Dohme LLC · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

carcinoma ovarian-cancer

ovarian cancer, carcinoma, ovarian epithelial, fallopian tube neoplasms, programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Related documents